论文部分内容阅读
目的探讨乳腺癌新辅助化疗对凋亡相关基因p53、bcl-2表达的影响及其意义。方法用免疫组织化学ABC法检测97例新辅助化疗(研究组)和同期76例未行新辅助化疗(对照组)的乳腺癌组织p53、bcl-2蛋白的表达,并结合5年无病生存率(DFS)进行分析。结果研究组p53阳性率为28.9%(28/97),对照组为38.2%(29/76);研究组bcl-2阳性率为40.2%(39/97),对照组为56.7%(43/76);研究组5年DFS为74.2%(72/97),对照组为60.5%(46/76),两者比较均有显著差异。结论新辅助化疗通过凋亡相关基因p53、bcl-2的表达影响预后。
Objective To investigate the effect of neoadjuvant chemotherapy on the expression of p53 and bcl-2 in breast cancer and its significance. Methods The expressions of p53 and bcl-2 protein in 97 cases of neoadjuvant chemotherapy (study group) and 76 cases of non-neoadjuvant chemotherapy (control group) were detected by immunohistochemical ABC method. Combined with 5 years disease-free survival Rate (DFS) for analysis. Results The positive rate of p53 was 28.9% (28/97) in the study group and 38.2% (29/76) in the control group. The positive rate of bcl-2 in the study group was 40.2% (39/97) and that in the control group was 56.7% (43 / 76). The 5-year DFS was 74.2% (72/97) in the study group and 60.5% (46/76) in the control group, both of which were significantly different. Conclusion Neoadjuvant chemotherapy affects the prognosis through the expression of p53 and bcl-2.